The NEI uses this U44 Notice of Funding Opportunity to support SBIR grant applications from small business concerns (SBCs) that propose to implement investigator-initiated, early-stage clinical trials with greater than minimal risk and typically are Phase I or II trials. The risk level of the U44 trial requires appropriate performance oversight and safety monitoring. For purposes of this NOFO, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders.
Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.
Deadlines:
Application Due Dates: Jan. 30, 2024; May 24, 2024; Sep 23, 2024; Jan 24, 2025; May 28, 2025; Sep 23, 2025; Jan 24, 2026; May 27, 2026; Sep 23, 2026
AIDS Due Dates: Jan. 7, May 7, Sep. 7
PAR-24-066 Expiration Date January 08, 2027
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Sep 23, 2024
Varies
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.